SomaLogic and Ambergen announce agreement for commercial applications of photocleavable biotin

November 29, 2011

SomaLogic, Inc. and AmberGen, Inc. announced today that they have entered into a licensing agreement whereby AmberGen will provide its proprietary photocleavable biotin reagent for the commercial use of SomaLogic's SOMAscanTM technology platform.

The biggest constraint on successful development of a high-throughput proteomic quantitation platform is achieving sufficient sensitivity. SomaLogic's innovative SOMAmer (Slow Off-rate Modified Aptamer) protein-capture reagents and their multiplex SOMAscan technology break through this limitation.

AmberGen has developed a range of novel molecules and compounds with photocleavable linkers, including a 5-prime photocleavable biotin, a light-activated biomolecule that it has licensed to SomaLogic. "AmberGen's photocleavable biotin element provides an efficient way to detect and measure the bound proteins as part of our SOMAscan™ platform" said Nick Saccomano, Ph.D., Chief Technology Officer at SomaLogic.

The SOMAscan™ technology platform utilizes SOMAmers to accurately screen dozens of patient samples simultaneously, allowing quantification of many specific proteins in a multiplexed, high-throughput manner. SomaLogic has thus far validated SOMAmers to a broad array of over 1000 different protein targets for use in biomarker discovery, diagnostics, and drug discovery and development.

"We look forward to exploring new applications for our photocleavable technologies with SomaLogic, as we continue to support their existing and emerging SOMAmer reagents," stated Christopher Sears, Ph.D., Chief Scientific Officer of AmberGen. "With both companies' commitment to developing tools for personalized medicine, there are ample opportunities for further collaboration."
-end-
About AmberGen, Inc.:

AmberGen is a privately held biomarker discovery and clinical diagnostic company based in Watertown, Massachusetts. AmberGen's proprietary molecular profiling technology enables physicians to more accurately make optimal therapeutic decisions tailored to individual patients. This is made possible by identifying unique molecular fingerprints in tumors, blood, and other biospecimens that are characteristic of specific diseases and their outcomes. AmberGen's approach combines unique patented technology in the area of proteomics, genomics, and bioinformatics.

About SomaLogic, Inc.:

SomaLogic, Inc., is a privately held biomarker discovery and clinical diagnostics company based in Boulder, Colorado. The company's mission is to use its proprietary Slow Off-rate Modified Aptamer ("SOMAmer") protein-capture reagents to develop enhanced protein analysis tools and reagents for the life sciences community, to facilitate biomarker discovery and validation for diagnostic and therapeutic applications, and to develop and commercialize clinical diagnostic products that will improve the delivery of healthcare by offering timely and precise diagnostic information to physicians and their patients. Further information about SomaLogic can be found at www.somalogic.com.

Contacts:

AmberGen, Inc.
Michele Sutherland
Director of Public Relations
P: 617-923-9999
Fax: 617-92309980

SomaLogic, Inc.
Fintan Steele, Ph.D.
Executive Director of Communications
P: 617-816-9834
fsteele@somalogic.com

SomaLogic, Inc.

Related Drug Discovery Articles from Brightsurf:

December special issue of SLAS Discovery features 'drug discovery targeting COVID-19'
The December edition of SLAS Discovery, ''Drug Discovery Targeting COVID-19'' is a special collection assembled by Associate Editor Timothy Spicer (Scripps, FL, USA), focusing on drug discovery efforts toward the current global pandemic of COVID-19caused by the novel coronavirus, SARS-CoV-2.

New cell profiling method could speed TB drug discovery
A new cell profiling technology combines high throughput imaging and machine learning to provide a rapid, cost-effective way to determine how specific compounds act to destroy the bacterium that causes tuberculosis.

An open-access tool to accelerate drug discovery
The Chemical Checker provides processed, harmonized and ready-to-use bioactivity information on more than 1M small molecules.

New macrolactone database could aid drug discovery, research
Researchers have created a free-to-use database of 14,000 known macrolactones -- large molecules used in drug development -- which contains information about the molecular characteristics, chemical diversity and biological activities of this structural class.

Discovery of a drug to rescue winter depression-like behavior
A group of animal biologists and chemists at the Institute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, has used a chemical genomics approach to explore the underlying mechanism of winter depression-like behavior and identified a drug that rescues winter depression-like behavior in medaka fish.

Fat-fighting drug discovery
Cancer-fighting compound fights obesity and diabetes.

New cell models for ocular drug discovery
Researchers at the University of Eastern Finland have developed two new cell models that can open up new avenues for ocular drug discovery.

Machine learning's next frontier: Epigenetic drug discovery
Scientists at Sanford Burnham Prebys Medical Discovery Institute have developed a machine-learning algorithm that gleans information from microscope images -- allowing for high-throughput epigenetic drug screens that could unlock new treatments for cancer, heart disease, mental illness and more.

Discovery of how colorectal cancer drug works will help more patients
Some colorectal cancer patients with a certain gene mutation benefit from a chemotherapy drug called cetuximab, although the mechanism of how this drug worked was unknown.

Speeding up the drug discovery process to help patients
An international research team is perfecting a method to predict the potential clinical implications of new drugs before clinical trials even start.

Read More: Drug Discovery News and Drug Discovery Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.